Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis.

Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis.

Show other versions (2)

Bibliographic Details
Main Authors:	Haldar, P, Brightling, C, Singapuri, A, Hargadon, B, Gupta, S, Monteiro, W, Bradding, P, Green, R, Wardlaw, A, Ortega, H, Pavord, I
Format:	Journal article
Language:	English
Published:	2014

Similar Items

Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: A 12-month follow-up analysis
by: Haldar, P, et al.
Published: (2014)

Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: A 12-month follow-up analysis
by: Haldar, P, et al.
Published: (2014)

Mepolizumab and exacerbations of refractory eosinophilic asthma.
by: Haldar, P, et al.
Published: (2009)

Mepolizumab in refractory eosinophilic asthma.
by: Pavord, I, et al.
Published: (2010)

Mepolizumab and the response to oral prednisolone in patients with severe eosinophilic asthma
by: Shrimanker, R, et al.
Published: (2017)

Characterisation of exacerbations of severe eosinophilic asthma (SEA) on mepolizumab compared to placebo
by: Shrimanker, R, et al.
Published: (2017)

Exacerbations of severe asthma in patients treated with mepolizumab
by: Shrimanker, R, et al.
Published: (2018)

Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthma
by: Yancey, S, et al.
Published: (2016)

Glucocorticoids and mepolizumab in eosinophilic asthma.
by: Bel, E, et al.
Published: (2014)

Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial.
by: Green, R, et al.
Published: (2002)

Mepolizumab, quality of life, and severe eosinophilic asthma.
by: Pavord, I
Published: (2017)

Mepolizumab treatment in patients with severe eosinophilic asthma.
by: Ortega, H, et al.
Published: (2014)

Comparison of airway immunopathology of eosinophilic bronchitis and asthma.
by: Brightling, C, et al.
Published: (2003)

Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma.
by: Bel, E, et al.
Published: (2014)

The role of oral methotrexate as a steroid sparing agent in refractory eosinophilic asthma.
by: Bilocca, D, et al.
Published: (2017)

Body mass and fat mass in refractory asthma: an observational 1 year follow-up study.
by: Bafadhel, M, et al.
Published: (2010)

Blood eosinophil depletion with mepolizumab, benralizumab and prednisolone in eosinophilic asthma
by: Moran, AM, et al.
Published: (2020)

Pathological features and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthma.
by: Berry, M, et al.
Published: (2007)

Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.
by: Ortega, H, et al.
Published: (2016)

Mepolizumab for eosinophilic COPD
by: Sciurba, F, et al.
Published: (2018)

Eosinophils in asthma and other allergic diseases.
by: Wardlaw, A, et al.
Published: (2000)

The significance of eosinophilic airway inflammation in asthma
by: Pavord, I, et al.
Published: (2002)

Eosinophil protein in airway macrophages: a novel biomarker of eosinophilic inflammation in patients with asthma.
by: Kulkarni, N, et al.
Published: (2010)

TH2 cytokine expression in bronchoalveolar lavage fluid T lymphocytes and bronchial submucosa is a feature of asthma and eosinophilic bronchitis.
by: Brightling, C, et al.
Published: (2002)

Non-eosinophilic corticosteroid unresponsive asthma.
by: Pavord, I, et al.
Published: (1999)

Evaluation of potential continuation rules for mepolizumab treatment of severe eosinophilic asthma.
by: Gunsoy, N, et al.
Published: (2017)

Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial.
by: Pavord, I, et al.
Published: (2012)

Vascular remodeling is a feature of asthma and nonasthmatic eosinophilic bronchitis.
by: Siddiqui, S, et al.
Published: (2007)

Sputum and bronchial submucosal IL-13 expression in asthma and eosinophilic bronchitis.
by: Berry, M, et al.
Published: (2004)

New insights into the role of the mast cell in asthma.
by: Brightling, C, et al.
Published: (2003)

Eosinophils in asthma and airway hyperresponsiveness.
by: Brightling, C, et al.
Published: (2004)

Qualitative analysis of high-resolution CT scans in severe asthma.
by: Gupta, S, et al.
Published: (2009)

Fractional exhaled nitric oxide and the peripheral blood eosinophil count as biomarkers of the response to mepolizumab in patients with severe eosinophilic asthma
by: Shrimanker, R, et al.
Published: (2018)

Depletion rate of blood eosinophils with mepolizumab, benralizumab and oral prednisolone in patients with severe asthma
by: Moran, A, et al.
Published: (2020)

Induced sputum inflammatory mediator concentrations in eosinophilic bronchitis and asthma.
by: Brightling, C, et al.
Published: (2000)

Induced sputum inflammatory mediator concentrations in eosinophilic bronchitis and asthma
by: Brightling, C, et al.
Published: (2000)

Quantitative analysis of high-resolution computed tomography scans in severe asthma subphenotypes.
by: Gupta, S, et al.
Published: (2010)

Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: Analysis of the REDES study
by: Ian Pavord, et al.
Published: (2023-04-01)

Clinical efficacy of mepolizumab in the treatment of severe eosinophilic asthma in children
by: V. N. Drozdov, et al.
Published: (2020-11-01)

Development of irreversible airflow obstruction in a patient with eosinophilic bronchitis without asthma.
by: Brightling, C, et al.
Published: (1999)